LONDON, UK: GSK plc and BELLUS Health Inc. have entered into a deal in which GSK will acquire BELLUS, a late-stage biopharmaceutical company for an approximate equity value of $2.0 billion. BELLUS Health is a Canada-based company that focuses on developing drugs to improve the lives of patients suffering from refractory chronic cough (RCC). With…